Assessment of the Value of Tumor Variation Profiling Perceived by Patients With Cancer

Butow, Phyllis; Davies, Grace; Napier, Christine E.; Schlub, Timothy E.; Best, Megan; Bartley, Nicci; Juraskova, Ilona; Meiser, Bettina; Ballinger, Mandy L.; Biesecker, Barbara B.; Goldstein, David; Thomas, David M.

doi:10.1001/jamanetworkopen.2020.4721

Cited by 8 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This association between WTP for cancer-related interventions and demographic characteristics is consistent with other studies. A number of studies have indicated that WTP monetary values are positively influenced by race/ethnicity [ 42 – 46 ], similar to our findings for the WTP of Jews versus other ethnic groups. As found here, most studies have shown that WTP amounts increase with respondent income [ 17 , 31 , 35 , 44 , 46 – 81 ].…”

Section: Discussionsupporting

confidence: 89%

Willingness to pay for an mRNA-based anti-cancer treatment: results from a contingent valuation study in Israel

Ben-Aharon,

Sergienko,

Iskrov

et al. 2024

Isr J Health Policy Res

View full text Add to dashboard Cite

Background mRNA technology is currently being investigated for a range of oncology indications. We assessed the willingness to pay (WTP) of the general population in Israel for a hypothetical novel mRNA-based treatment for oncology indications. Methods We used a contingent valuation methodology to elicit WTP using a web-based questionnaire. A sample of adult participants were presented with a hypothetical scenario in which an mRNA-based intervention increased the likelihood of a cure for various cancer types from 20% to 40% (half of the sample), or 60% (the other half of the sample). Results 531 respondents completed the questionnaire. The mean, median and mode WTP for the proposed hypothetical treatment in both scenarios were ILS65,000 (± ILS114,000), ILS20,000 and ILS50,000, respectively (1USD = 3.4ILS). The WTP was skewed towards zero, and 9.6% of the respondents were not willing to pay any amount. WTP higher amounts was significantly associated with higher income (p < 0.01), self-reported good health (p < 0.05), supplementary health insurance (p < 0.05), Jews compared to other populations (p < 0.01), interest in technology (p < 0.001) and a tendency to adopt medical innovations (p < 0.001). No statistical difference between the 40% vs. the 60% potential cure scenarios was found. Logistic and OLS regressions indicated that age, religion, income, and interest in adopting medical innovations were the best predictors of respondents' WTP. Conclusion Despite the scientific breakthroughs in oncology treatment over the last few decades, many types of cancer are still incurable. Given the expected development of innovative mRNA-based treatments for cancer, these results should inform policymakers, the pharmaceutical industry and other stakeholders on the future coverage and reimbursement of these technologies incorporating patients’ and societal views. To date, WTP considerations have not been given much weight in prioritization of drug reimbursement processes, neither in Israel nor in other countries. As a pioneer in adoption of the mRNA technology, Israel can also lead the incorporation of WTP considerations in this field.

show abstract

Section: Discussionsupporting

confidence: 89%

Willingness to pay for an mRNA-based anti-cancer treatment: results from a contingent valuation study in Israel

Ben-Aharon,

Sergienko,

Iskrov

et al. 2024

Isr J Health Policy Res

View full text Add to dashboard Cite

show abstract

“…Table 1 includes three publications [7][8][9] from a single survey of 100 patients with breast cancer recruited during their first visit to the University of Texas MD Anderson Cancer Center who were asked to provide consent for tissue banking. Table 2 includes three publications [10][11][12] from the Psychosocial Issues in Genomics in Oncology (PiGeOn) Project, a substudy of the Molecular Screening and Therapeutics Program in Sydney, Australia, which provided tumor molecular profiling to 1,000 patients with advanced cancer for whom there are no further therapeutic options. Table 2 also includes two publications by Blijsma et al [13,14] who interviewed patients (twice) regarding attitudes toward secondary germline findings from tumor NGS and then, shortly thereafter, conducted a third set of more in-depth interviews with the same patients, summarized in a separate publication.…”

Section: Patientsmentioning

confidence: 99%

Patients’ and Oncologists’ Knowledge and Expectations Regarding Tumor Multigene Next-Generation Sequencing: A Narrative Review

et al. 2021

View full text Add to dashboard Cite

Background. Tumor multigene next-generation sequencing (NGS) is increasingly being offered to cancer patients to guide clinical management and determine eligibility for clinical trials. We undertook a review of studies examining the knowledge and attitudes of patients and oncologists regarding the primary results and potential secondary findings of such testing. Materials and Methods. A search was conducted through the MEDLINE database using the following keywords: "neoplasms" and "molecular sequencing / genome sequencing / tumor profiling / NGS / whole exome sequencing" and "patient / oncologist" and "knowledge / attitudes / satisfaction / experience / evaluation / perspective / practice / preference." Articles meeting the inclusion criteria and additional relevant articles from their references were selected. Results. From 1,142 publications identified by the search and 9 from references, 21 publications were included in the final review. Patients generally had positive attitudes

show abstract

“…Qualitative studies have reported that patients with advanced cancer offered tumor testing had positive views about, and unequivocally accepted, screening for somatic tumor genetic variants linked to possible cancer treatments (Best et al, 2019; Best et al, 2020; Hamilton et al, 2017; Liang et al, 2017). In a quantitative assessment of advanced cancer patients' perceived value of CGTP, we found that as many as 89% of such patients would have CGTP for as little as a 1% actionable return rate (Butow, Davies, et al, 2020). In these studies, patients perceived CGTP to have high importance even though they had had poor to moderate knowledge of CGTP (Davies et al, 2020; Liang et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Psychological predictors of advanced cancer patients’ preferences for return of results from comprehensive tumor genomic profiling

Meiser

Butow

Davies

et al. 2021

American J of Med Genetics Pt A

Self Cite

View full text Add to dashboard Cite

This study assessed the psychological predictors of preferences for return of comprehensive tumor genomic profiling (CTGP) results in patients with advanced cancers, enrolled in the Molecular Screening and Therapeutics Program. Patients completed a questionnaire prior to undergoing CTGP. Of the 1434 who completed a questionnaire, 96% would like to receive results that can guide treatment for their cancer, and preference for receiving this type of result was associated with lower tolerance of uncertainty. Sixty-four percent would like to receive results that cannot guide treatment, and lower tolerance of uncertainty, self-efficacy, and perceived importance were associated with this preference. Fifty-nine percent would like to receive variants of unknown significance, which was associated with lower tolerance of uncertainty, higher self-efficacy, and perceived importance. Eighty-six percent wanted to receive germline results that could inform family risk. This was associated with higher self-efficacy, perceived importance, and perceived susceptibility. Although most patients wanted to receive all types of results, given the differing patient preferences regarding the return of results depending on the utility of the different types of results, it appears critical to safeguard patient understanding of result utility to achieve informed patient choices. This should be accompanied by appropriate consent processes.

show abstract

Assessment of the Value of Tumor Variation Profiling Perceived by Patients With Cancer

Cited by 8 publications

References 34 publications

Willingness to pay for an mRNA-based anti-cancer treatment: results from a contingent valuation study in Israel

Willingness to pay for an mRNA-based anti-cancer treatment: results from a contingent valuation study in Israel

Patients’ and Oncologists’ Knowledge and Expectations Regarding Tumor Multigene Next-Generation Sequencing: A Narrative Review

Psychological predictors of advanced cancer patients’ preferences for return of results from comprehensive tumor genomic profiling

Contact Info

Product

Resources

About